3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
12
Neoplasms by Site
1
Neoplasms
1
ESR1 Gene Mutation
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms, Male
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Advanced ER+, HER2-Negative Breast Cancer
1
Advanced Breast Cancer
1
Interventions
Temozolomide
3
Irinotecan
3
tozuleristide
2
selpercatinib
2
lenvatinib
2
gadobenic acid
2
avelumab
2
Radiation
2
Paclitaxel
2
Leflunomide
2
Immunotherapy
2
Gemcitabine
2
Everolimus
2
Cisplatin
2
Carboplatin
2
Cancer Vaccines
2
Bevacizumab
2
Adjuvants, Immunologic
2
ridaforolimus
1
regorafenib
1
prinomastat
1
pomalidomide
1
perillyl alcohol
1
pemigatinib
1
pembrolizumab
1
pamiparib
1
omburtamab I-131
1
irinotecan sucrosofate
1
interferon gamma-1b
1
infigratinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Central Nervous System Neoplasms
×
elacestrant
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled